ALFA Finder| Revenue growth | 32.2% YoY for FY26; 21.2% for Q4 FY26. |
|---|---|
| Margins | FY26 Adjusted EBITDA margin improved to 23.8% from 22.9%. |
| Demand visibility | Strong, driven by rising global CKD prevalence and under-penetration. |
| Management confidence | High, citing scalability of operating model across global markets. |
Growth
FY26 Revenue grew 32.2% YoY to ₹998.8 Cr; Adjusted PAT surged 74.6% to ₹128.3 Cr.
Outlook
Focus on deepening India presence and scaling international businesses in Uzbekistan, Philippines, and Saudi Arabia for FY27.
Risks
High concentration of Chronic Kidney Disease risk factors (Diabetes/Hypertension); clinical replicability challenges in non-standardized specialties.
Earnings Call filed with NSE, NSE: NEPHROPLUS. Summary written with AI assistance from the document.
Nephrocare Health Services Ltd: key numbers
- Share price
- ₹630.40
- Market cap
- ₹6,325 Cr
- Revenue (annual)
- ₹998.8 Cr
- Net profit (annual)
- ₹76.84 Cr
- P/E (TTM)
- 49.4×Sector 54.5×
- Promoter holding
- 58.31%-5.54% QoQ
- FII holding
- 11.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nephrocare Health Services Ltd
All →Nephrocare Health Services Earnings Call Transcript: Key Takeaways
Revenue grew a healthy 23.5%, but adjusted EBITDA lagged and H1 margin fell about 80bps to 23%. Management deflected on pricing, FX and margin detail, relying on 'healthy range' language and long-term guidance.
Nephrocare Health Services Other Announcement
Nephrocare filed Crisil's monitoring agency report on IPO proceeds for the quarter ended 30 September 2026. The report shows no deviation from the stated objects.
Nephrocare Health Services Investor Presentation: Key Takeaways
H1FY27 revenue ₹585.2 Cr (+23.6% YoY), Adj EBITDA ₹134.4 Cr (+15.3%), Adj PAT ₹76.1 Cr (+34.7%). Expansion via acquisitions in Philippines, Kazakhstan and Saudi Arabia.
Nephrocare Health Services Results Update
Nephrocare Health Services released its Q2 and H1 FY27 results press release. Revenue and adjusted profit grew year-on-year, alongside network expansion into Kazakhstan.
Nephrocare Health Services Q2 FY27 Results: Turns Profitable, Net Profit ₹33.5 Cr
Nephrocare Health Services Ltd reported revenue from operations of ₹303.4 Cr (+23.5% YoY) and net profit of ₹33.5 Cr for Q2 FY27.
- Key figure
- Net profit ₹33.5 Cr
Nephrocare Health Services Legal & Regulatory
Nephrocare's Uzbek subsidiary won a court ruling invalidating a ₹14.79 crore tax demand. The tax department must reconsider the audit, and the decision remains appealable.
- Value
- ₹14.79 Cr